BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO) is a Healthcare stock tracked by StreetAlpha. It last closed at $68.39 on Sep 15, down 24.15% on the day. BBIO reports earnings on Wed, Oct 28, 2026. The average 12-month price target from 11 analysts is $106.82 (+56.2% from the last close), with a high of $120.00 and a low of $93.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in BBIO, 67% of them bullish and 33% bearish. In the past 30 days there were 5 dark pool prints totaling $17.8M, the largest $13.6M.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 11 analysts who set a price target on BBIO in the past 90 days. The average target is $106.82, with a high of $120.00 and a low of $93.00, compared with the last close of $68.39.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| Sep 1 | Mizuho | Target raised | Buy | $96 → $110 |
| Aug 12 | Truist Securities | Maintained | Buy | $107 |
| Aug 12 | Canaccord Genuity | Target raised | Buy | $104 → $106 |
| Aug 12 | JP Morgan | Maintained | Buy | $111 |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBIO is in one of them and how their past BBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BBIO in an article yet. Here's the latest on the wider market.